The CGMS® iPro™ Continuous Glucose Recorder delivers the information you need to optimize therapy adjustments

  • The utility and accuracy of Medtronic CGMS technology are supported by more than 200 clinical references
  • Numerous studies have reported that CGM data facilitates clinical decisions that lead toimproved glycemic control1–5

Studies show the clinical value of CGM data

  • 85% of participants (N = 322) had distinctive "peaks" and "drop-offs" subject to considerable variability6
  • Use of CGMS is a minimally invasive method of determining individual basal rates vs BG meter testing6
  • The CGM group showed significantly shorter duration of hypoglycemia than the BG group, both overnight and overall7
  • A statistically significant change in A1C, from 8.6 ± 1.5% to 8.4 ± 1.3% from 3 months before CGMS to 6 months after4

Helps individualize therapy for all diabetes patients

  • Can assist you in designing an individualized diabetes treatment program based on detailed glycemic profiles
  • May be of particular use in evaluating the following conditions and situations:
    • Those who experience dangerous lows and highs
    • Those who experience hypoglycemia unawareness
    • Those who desire better control
    • Those with elevated A1C levels
    • Women with gestational diabetes
    • Women with diabetes who are pregnant
1
Skyler JS. The economic burden of diabetes and the benefits of improved glycemic control: the potential role of a continuous glucose monitoring system. Diabetes Technol Ther. 2000;2(suppl 1):S7-S12.
2
Gross TM, Mastrototaro JJ. Efficacy and reliability of the continuous glucose monitoring system. Diabetes Technol Ther. 2000;2(suppl 1):S19-S26.
3
Gross TM, Bode BW, Einhorn D, et al. Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use. Diabetes Technol Ther. 2000;2(1):49-56.
4
Kaufman FR, Gibson LC, Halvorson M, Carpenter S, Fisher LK, Pitukcheewanont P. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care. 2001;24(12):2030-2034.
5
Bode BW, Gross TM, Thornton KR, Mastrototaro JJ. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract. 1999;46(3):183-190.
6
Scheiner G, Boyer BA. Characteristics of basal insulin requirements by age and gender in Type-1 diabetes patients using insulin pump therapy. Diabetes Res Clin Pract. 2005;69(1):14-21.
7
Tanenberg R, Bode B, Lane W, et al. Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc. 2004;79(12):1521-1526.